170 related articles for article (PubMed ID: 8088611)
1. A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer.
Kirmani S; Braly PS; McClay EF; Saltzstein SL; Plaxe SC; Kim S; Cates C; Howell SB
Gynecol Oncol; 1994 Sep; 54(3):338-44. PubMed ID: 8088611
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
Howell SB; Kirmani S; Lucas WE; Zimm S; Goel R; Kim S; Horton MC; McVey L; Morris J; Weiss RJ
J Clin Oncol; 1990 Jan; 8(1):137-45. PubMed ID: 2295904
[TBL] [Abstract][Full Text] [Related]
3. A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer.
Polyzos A; Tsavaris N; Kosmas C; Giannikos L; Katsikas M; Kalahanis N; Karatzas G; Christodoulou K; Giannakopoulos K; Stamatiadis D; Katsilambros N
Oncology; 1999; 56(4):291-6. PubMed ID: 10343192
[TBL] [Abstract][Full Text] [Related]
4. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer.
Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T
Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759
[TBL] [Abstract][Full Text] [Related]
6. Long-term survival with consolidation intraperitoneal chemotherapy for patients with advanced ovarian cancer with pathological complete remission.
Tournigand C; Louvet C; Molitor JL; Fritel X; Dehni N; Sezeur A; Pigné A; Cady J; Milliez J; de Gramont A
Gynecol Oncol; 2003 Nov; 91(2):341-5. PubMed ID: 14599864
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest.
Gadducci A; Carnino F; Chiara S; Brunetti I; Tanganelli L; Romanini A; Bruzzone M; Conte PF
Gynecol Oncol; 2000 Feb; 76(2):157-62. PubMed ID: 10637064
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal cisplatin and intravenous paclitaxel in the treatment of epithelial ovarian cancer patients with a positive second look.
Makhija S; Sabbatini P; Aghajanian C; Venkatraman E; Spriggs DR; Barakat R
Gynecol Oncol; 2000 Oct; 79(1):28-32. PubMed ID: 11006026
[TBL] [Abstract][Full Text] [Related]
9. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
10. Mature results of a prospective randomized trial comparing a three-weekly with an accelerated weekly schedule of cisplatin in advanced ovarian carcinoma.
Cocconi G; Bella M; Lottici R; Leonardi F; Ceci G; Passalacqua R; Di Blasio B; Bordi C; Biscottini B; Melpignano M; De Biasi D; Finardi C; Bacchi M
Am J Clin Oncol; 1999 Dec; 22(6):559-67. PubMed ID: 10597739
[TBL] [Abstract][Full Text] [Related]
11. Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.
Barlin JN; Dao F; Bou Zgheib N; Ferguson SE; Sabbatini PJ; Hensley ML; Bell-McGuinn KM; Konner J; Tew WP; Aghajanian C; Chi DS
Gynecol Oncol; 2012 Jun; 125(3):621-4. PubMed ID: 22446622
[TBL] [Abstract][Full Text] [Related]
12. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
[TBL] [Abstract][Full Text] [Related]
13. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B.
Miller AA; Herndon JE; Hollis DR; Ellerton J; Langleben A; Richards F; Green MR
J Clin Oncol; 1995 Aug; 13(8):1871-9. PubMed ID: 7636529
[TBL] [Abstract][Full Text] [Related]
14. High-intensity intravenous cyclophosphamide and cisplatin, interim surgical debulking, and intraperitoneal cisplatin in advanced ovarian carcinoma: a pilot trial with ten-year follow-up.
Shapiro F; Schneider J; Markman M; Reichman BS; Venkatraman E; Barakat R; Almadrones L; Spriggs D
Gynecol Oncol; 1997 Oct; 67(1):39-45. PubMed ID: 9345354
[TBL] [Abstract][Full Text] [Related]
15. Long-term results in patients with advanced epithelial ovarian carcinoma treated with a combination of cisplatin, doxorubicin, and cyclophosphamide.
Colozza M; Mosconi AM; Gori S; Belsanti V; Basurto C; De Angelis V; Giansanti M; Tonato M
Am J Clin Oncol; 1997 Oct; 20(5):522-6. PubMed ID: 9345342
[TBL] [Abstract][Full Text] [Related]
16. Prospective sequential trials of induction weekly cisplatin followed by monthly cisplatin, doxorubicin, cyclophosphamide and paclitaxel and cisplatin in optimal (< or = 1 cm) stage III and IV ovarian cancer.
Piver MS; Eltabbakh GH; Hempling RE; Recio FO; Blumenson LE
Eur J Gynaecol Oncol; 1998; 19(1):5-10. PubMed ID: 9476049
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer.
Yen MS; Juang CM; Lai CR; Chao GC; Ng HT; Yuan CC
Int J Gynaecol Obstet; 2001 Jan; 72(1):55-60. PubMed ID: 11146078
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel with carboplatin versus paclitaxel with carboplatin alternating with cisplatin as first-line chemotherapy in advanced epithelial ovarian cancer: preliminary results of a Hellenic Cooperative Oncology Group study.
Skarlos DV; Aravantinos G; Kosmidis P; Athanassiadis A; Stathopoulos GP; Pavlidis N; Bafaloukos D; Karphathios S; Papakostas P; Bamia C; Fountzilas G
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-57-S15-61. PubMed ID: 9346224
[TBL] [Abstract][Full Text] [Related]
19. Consolidation with intraperitoneal cisplatin in first-line therapy of advanced ovarian cancer.
Beller U; Speyer J; Colombo N; Sorich J; Wernz J; Hochster H; Zeleniuch-Jacquotte A; Porges R; Beckman EM
J Clin Oncol; 1991 May; 9(5):809-17. PubMed ID: 2016624
[TBL] [Abstract][Full Text] [Related]
20. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma.
Piver MS; Lele SB; Marchetti DL; Baker TR; Emrich LJ; Hartman AB
J Clin Oncol; 1988 Nov; 6(11):1679-84. PubMed ID: 3183700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]